drugset / Trial / NCT00117533
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Phase 4
Unknown
20 enrolled
National Taiwan University Hospital
National Health Research Institutes, Taiwan · collabNational Science and Technology Council, Taiwan · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D patients who are also infected by hepatitis B virus (HBV). The purpose of this study is to test this hypothesis. The investigators will use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic hepatitis D virus (HDV) and HBV infection. A 24-week course of combination therapy pegylated IFN+RBV will be used.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |
| Subject | pegylated IFN alfa-2b | Unknown | — | — |